Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 357

1.

Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey.

Blagojevic J, Bellando-Randone S, Abignano G, Avouac J, Cometi L, Czirják L, Denton CP, Distler O, Frerix M, Guiducci S, Huscher D, Jaeger VK, Lóránd V, Maurer B, Nihtyanova S, Riemekasten G, Siegert E, Tarner IH, Vettori S, Walker UA, Allanore Y, Müller-Ladner U, Del Galdo F, Matucci-Cerinic M; EUSTAR co-workers.

Arthritis Res Ther. 2019 Jan 24;21(1):35. doi: 10.1186/s13075-019-1822-1.

2.

Performance of candidate serum biomarkers for systemic sclerosis-interstitial lung disease.

Elhai M, Hoffmann-Vold AM, Avouac J, Pezet S, Cauvet A, Leblond A, Fretheim H, Garen T, Kuwana M, Molberg Ø, Allanore Y.

Arthritis Rheumatol. 2019 Jan 9. doi: 10.1002/art.40815. [Epub ahead of print]

PMID:
30624031
3.

Targeting Costimulatory Pathways in Systemic Sclerosis.

Boleto G, Allanore Y, Avouac J.

Front Immunol. 2018 Dec 18;9:2998. doi: 10.3389/fimmu.2018.02998. eCollection 2018. Review.

4.

Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study.

Matucci-Cerinic M, Allanore Y, Kavanaugh A, Buch MH, Schulze-Koops H, Kucharz EJ, Woehling H, Babic G, Poetzl J, Davis A, Schwebig A.

RMD Open. 2018 Nov 14;4(2):e000757. doi: 10.1136/rmdopen-2018-000757. eCollection 2018.

5.

Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension.

D'Alto M, Romeo E, Argiento P, Mattera Iacono A, Vettori S, Riccardi A, Allanore Y, D'Andrea A, Rea G, Bossone E, Valentini G, Naeije R, Golino P.

Pulm Circ. 2019 Jan-Mar;9(1):2045894018816089. doi: 10.1177/2045894018816089. Epub 2018 Nov 13.

6.

Systemic sclerosis: state of the art on clinical practice guidelines.

Smith V, Scirè CA, Talarico R, Airo P, Alexander T, Allanore Y, Bruni C, Codullo V, Dalm V, De Vries-Bouwstra J, Della Rossa A, Distler O, Galetti I, Launay D, Lepri G, Mathian A, Mouthon L, Ruaro B, Sulli A, Tincani A, Vandecasteele E, Vanhaecke A, Vanthuyne M, Van den Hoogen F, Van Vollenhoven R, Voskuyl AE, Zanatta E, Bombardieri S, Burmester G, Eurico FJ, Frank C, Hachulla E, Houssiau F, Mueller-Ladner U, Schneider M, van Laar JM, Vieira A, Cutolo M, Mosca M, Matucci-Cerinic M.

RMD Open. 2018 Oct 18;4(Suppl 1):e000782. doi: 10.1136/rmdopen-2018-000782. eCollection 2018.

7.

Impact of EUSTAR standardized training on accuracy of modified Rodnan skin score in patients with systemic sclerosis.

Park JW, Ahn GY, Kim JW, Park ES, Kang JH, Chang SH, Choi IA, Yoo SJ, Park JK, Shin K, Park YB, Jun JB, Czirják L, Allanore Y, Matucci-Cerinic M, Lee EB.

Int J Rheum Dis. 2019 Jan;22(1):96-102. doi: 10.1111/1756-185X.13433. Epub 2018 Nov 5.

PMID:
30398033
8.

Regulatory T Cells in Systemic Sclerosis.

Frantz C, Auffray C, Avouac J, Allanore Y.

Front Immunol. 2018 Oct 15;9:2356. doi: 10.3389/fimmu.2018.02356. eCollection 2018. Review.

9.

MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, González-Pérez MI, Mejía M, Buendía-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou K, van Moorsel CHM, van der Vis J, de Man YA, Grutters JC, Wang Y, Borie R, Wemeau-Stervinou L, Wallaert B, Flipo RM, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Marchand-Adam S, Frazier A, Richette P, Allanore Y, Sibilia J, Dromer C, Richez C, Schaeverbeke T, Lioté H, Thabut G, Nathan N, Amselem S, Soubrier M, Cottin V, Clément A, Deane K, Walts AD, Fingerlin T, Fischer A, Ryu JH, Matteson EL, Niewold TB, Assayag D, Gross A, Wolters P, Schwarz MI, Holers M, Solomon JJ, Doyle T, Rosas IO, Blauwendraat C, Nalls MA, Debray MP, Boileau C, Crestani B, Schwartz DA, Dieudé P.

N Engl J Med. 2018 Dec 6;379(23):2209-2219. doi: 10.1056/NEJMoa1801562. Epub 2018 Oct 20.

PMID:
30345907
10.

18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis.

Bellando-Randone S, Tartarelli L, Cavigli E, Tofani L, Bruni C, Lepri G, Blagojevic J, Moggi-Pignone A, Mihai C, Avouac J, Passeri A, De Cristofaro MT, Distler O, Allanore Y, Guiducci S, Matucci-Cerinic M.

Ann Rheum Dis. 2018 Oct 18. pii: annrheumdis-2018-213376. doi: 10.1136/annrheumdis-2018-213376. [Epub ahead of print] No abstract available.

PMID:
30337426
11.

Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database.

Carreira PE, Carmona L, Joven BE, Loza E, Andreu JL, Riemekasten G, Vettori S, Balbir-Gurman A, Airò P, Walker UA, Damjanov N, Matucci-Cerinic M, Ananieva LP, Rednic S, Czirják L, Distler O, Farge D, Hesselstrand R, Corrado A, Caramaschi P, Tikly M, Allanore Y; and the EUSTAR co-authors.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):68-75. Epub 2018 Sep 29.

12.

European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis.

Abignano G, Blagojevic J, Bissell LA, Dumitru RB, Eng S, Allanore Y, Avouac J, Bosello S, Denton CP, Distler O, Ferraccioli G, Jordan S, Matucci-Cerinic M, Ong V, Messenger M, Hutchinson M, Buch MH, Emery P, Del Galdo F.

Rheumatology (Oxford). 2019 Feb 1;58(2):254-259. doi: 10.1093/rheumatology/key271.

PMID:
30239834
13.

Linking systemic angiogenic markers to synovial vascularization in rheumatoid arthritis.

Leblond A, Pezet S, Trouvin AP, Elhai M, Gonzalez V, Allanore Y, Avouac J.

PLoS One. 2018 Sep 6;13(9):e0203607. doi: 10.1371/journal.pone.0203607. eCollection 2018.

14.

From VEDOSS to established systemic sclerosis diagnosis according to ACR/EULAR 2013 classification criteria: a French-Italian capillaroscopic survey.

Vasile M, Avouac J, Sciarra I, Stefanantoni K, Iannace N, Cravotto E, Valesini G, Allanore Y, Riccieri V.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):82-87. Epub 2018 Aug 29.

PMID:
30183599
15.

The Nrf2-Antioxidant Response Element Signaling Pathway Controls Fibrosis and Autoimmunity in Scleroderma.

Kavian N, Mehlal S, Jeljeli M, Saidu NEB, Nicco C, Cerles O, Chouzenoux S, Cauvet A, Camus C, Ait-Djoudi M, Chéreau C, Kerdine-Römer S, Allanore Y, Batteux F.

Front Immunol. 2018 Aug 16;9:1896. doi: 10.3389/fimmu.2018.01896. eCollection 2018.

16.

T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis.

Boleto G, Guignabert C, Pezet S, Cauvet A, Sadoine J, Tu L, Nicco C, Gobeaux C, Batteux F, Allanore Y, Avouac J.

Arthritis Res Ther. 2018 Aug 29;20(1):197. doi: 10.1186/s13075-018-1694-9.

17.

Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database.

Carreira PE, Carmona L, Joven BE, Loza E, Andréu JL, Riemekasten G, Vettori S, Balbir-Gurman A, Airò P, Walker U, Damjanov N, Matucci-Cerinic M, Ananieva LP, Rednic S, Czirják L, Distler O, Farge D, Hesselstrand R, Corrado A, Caramaschi P, Tikly M, Allanore Y.

Scand J Rheumatol. 2019 Jan;48(1):42-51. doi: 10.1080/03009742.2018.1459830. Epub 2018 Jul 24.

PMID:
30039730
18.

Interstitial pneumonia with autoimmune features: a new classification still on the move.

Cavagna L, Gonzalez Gay MA, Allanore Y, Matucci-Cerinic M.

Eur Respir Rev. 2018 Jun 27;27(148). pii: 180047. doi: 10.1183/16000617.0047-2018. Print 2018 Jun 30. No abstract available.

19.

Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.

Wu W, Jordan S, Becker MO, Dobrota R, Maurer B, Fretheim H, Ye S, Siegert E, Allanore Y, Hoffmann-Vold AM, Distler O.

Ann Rheum Dis. 2018 Sep;77(9):1326-1332. doi: 10.1136/annrheumdis-2018-213201. Epub 2018 Jun 6.

PMID:
29875097
20.

Soluble CD163 as a Potential Biomarker in Systemic Sclerosis.

Frantz C, Pezet S, Avouac J, Allanore Y.

Dis Markers. 2018 Apr 1;2018:8509583. doi: 10.1155/2018/8509583. eCollection 2018.

21.

Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study.

Jaeger VK, Valentini G, Hachulla E, Cozzi F, Distler O, Airó P, Czirják L, Allanore Y, Siegert E, Rosato E, Matucci-Cerinic M, Caimmi C, Henes J, Carreira PE, Smith V, Del Galdo F, Denton CP, Ullman S, De Langhe E, Riccieri V, Alegre-Sancho JJ, Rednic S, Müller-Ladner U, Walker UA; EUSTAR coauthors.

Arthritis Rheumatol. 2018 Nov;70(11):1829-1834. doi: 10.1002/art.40557. Epub 2018 Sep 24.

PMID:
29781588
22.

Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study.

Allanore Y, Distler O, Jagerschmidt A, Illiano S, Ledein L, Boitier E, Agueusop I, Denton CP, Khanna D.

Arthritis Rheumatol. 2018 Oct;70(10):1634-1643. doi: 10.1002/art.40547. Epub 2017 Nov 6.

PMID:
29732731
23.

Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.

Ingegnoli F, Schioppo T, Allanore Y, Caporali R, Colaci M, Distler O, Furst DE, Hunzelmann N, Iannone F, Khanna D, Matucci-Cerinic M.

Semin Arthritis Rheum. 2018 Apr 4. pii: S0049-0172(18)30013-1. doi: 10.1016/j.semarthrit.2018.03.019. [Epub ahead of print] Review.

PMID:
29706243
24.

Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.

Boleto G, Avouac J, Wipff J, Forien M, Dougados M, Roux C, Kahan A, Dieude P, Allanore Y.

Semin Arthritis Rheum. 2018 Oct;48(2):149-154. doi: 10.1016/j.semarthrit.2018.02.010. Epub 2018 Feb 21.

PMID:
29548542
25.

Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry.

Montani D, Henry J, O'Connell C, Jaïs X, Cottin V, Launay D, Habib G, Bourdin A, Jevnikar M, Savale L, Rottat L, Simonneau G, Sitbon O, Humbert M, Allanore Y.

Respiration. 2018;95(4):244-250. doi: 10.1159/000485631. Epub 2018 Feb 28.

PMID:
29490304
26.

Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study.

Ndosi M, Alcacer-Pitarch B, Allanore Y, Del Galdo F, Frerix M, García-Díaz S, Hesselstrand R, Kendall C, Matucci-Cerinic M, Mueller-Ladner U, Sandqvist G, Torrente-Segarra V, Schmeiser T, Sierakowska M, Sierakowska J, Sierakowski S, Redmond A.

Ann Rheum Dis. 2018 Jul;77(7):1032-1038. doi: 10.1136/annrheumdis-2017-212412. Epub 2018 Feb 20.

27.

Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis.

Distler O, Allanore Y, Denton CP, Matucci-Cerinic M, Pope JE, Hinzmann B, Davies S, de Oliveira Pena J, Khanna D.

Rheumatology (Oxford). 2018 May 1;57(5):813-817. doi: 10.1093/rheumatology/kex504.

28.

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.

Adler S, Huscher D, Siegert E, Allanore Y, Czirják L, DelGaldo F, Denton CP, Distler O, Frerix M, Matucci-Cerinic M, Mueller-Ladner U, Tarner IH, Valentini G, Walker UA, Villiger PM, Riemekasten G; EUSTAR co-workers on behalf of the DeSScipher project research group within the EUSTAR network.

Arthritis Res Ther. 2018 Jan 30;20(1):17. doi: 10.1186/s13075-018-1517-z.

29.

Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis.

Allanore Y, Distler O, Matucci-Cerinic M, Denton CP.

Arthritis Rheumatol. 2018 Feb;70(2):162-170. doi: 10.1002/art.40377. Epub 2018 Jan 22. Review.

30.

Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France.

Avouac J, Moltó A, Abitbol V, Etcheto A, Salcion A, Gutermann L, Klotz C, Elhai M, Cohen P, Soret PA, Morin F, Conort O, Chast F, Goulvestre C, Jeunne CL, Chaussade S, Kahan A, Roux C, Allanore Y, Dougados M.

Semin Arthritis Rheum. 2018 Apr;47(5):741-748. doi: 10.1016/j.semarthrit.2017.10.002. Epub 2017 Oct 5.

PMID:
29102156
31.

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Arnold MB, Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE, Pope JE.

Rheumatology (Oxford). 2018 Jan 1;57(1):152-157. doi: 10.1093/rheumatology/kex396.

32.

Prevalence and Disease-Specific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study.

John G, Avouac J, Piantoni S, Polito P, Fredi M, Cozzi F, Airò P, Truchetet ME, Franceschini F, Allanore Y, Chizzolini C.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1218-1227. doi: 10.1002/acr.23454. Epub 2018 Jun 19.

PMID:
29073343
33.

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE.

Ann Rheum Dis. 2018 Feb;77(2):212-220. doi: 10.1136/annrheumdis-2017-211682. Epub 2017 Oct 24.

34.

Points to consider for skin ulcers in systemic sclerosis.

Galluccio F, Allanore Y, Czirjak L, Furst DE, Khanna D, Matucci-Cerinic M.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v67-v71. doi: 10.1093/rheumatology/kex200. Review.

35.

Points to consider when doing a trial primarily involving the heart.

Allanore Y, Distler O, Walker UA, Khanna D, Furst DE, Meune C.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v12-v16. doi: 10.1093/rheumatology/kex198. Review.

36.

Muscle involvement in systemic sclerosis: points to consider in clinical trials.

Walker UA, Clements PJ, Allanore Y, Distler O, Oddis CV, Khanna D, Furst DE.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v38-v44. doi: 10.1093/rheumatology/kex196. Review.

37.

Points to consider for designing trials in systemic sclerosis patients with arthritic involvement.

Clements P, Allanore Y, Furst DE, Khanna D.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v23-v26. doi: 10.1093/rheumatology/kex194. Review.

38.

The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study.

John G, Allanore Y, Polito P, Piantoni S, Fredi M, Avouac J, Franceschini F, Truchetet ME, Cozzi F, Airo P, Chizzolini C.

Rheumatology (Oxford). 2017 Nov 1;56(11):1874-1883. doi: 10.1093/rheumatology/kex230.

PMID:
28977630
39.

An international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaud's phEnomenon (SUNSHINE survey).

Ingegnoli F, Ughi N, Dinsdale G, Orenti A, Boracchi P, Allanore Y, Foeldvari I, Sulli A, Cutolo M, Smith V, Herrick AL; EULAR Study Group on Microcirculation in RheumaticDiseases.

Rheumatol Int. 2017 Nov;37(11):1879-1890. doi: 10.1007/s00296-017-3808-0. Epub 2017 Sep 11.

PMID:
28894946
40.

Mapping and predicting mortality from systemic sclerosis.

Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G, Airò P, Joven B, Vettori S, Cozzi F, Ullman S, Czirják L, Tikly M, Müller-Ladner U, Caramaschi P, Distler O, Iannone F, Ananieva LP, Hesselstrand R, Becvar R, Gabrielli A, Damjanov N, Salvador MJ, Riccieri V, Mihai C, Szücs G, Walker UA, Hunzelmann N, Martinovic D, Smith V, Müller CS, Montecucco CM, Opris D, Ingegnoli F, Vlachoyiannopoulos PG, Stamenkovic B, Rosato E, Heitmann S, Distler JHW, Zenone T, Seidel M, Vacca A, Langhe E, Novak S, Cutolo M, Mouthon L, Henes J, Chizzolini C, Mühlen CAV, Solanki K, Rednic S, Stamp L, Anic B, Santamaria VO, De Santis M, Yavuz S, Sifuentes-Giraldo WA, Chatelus E, Stork J, Laar JV, Loyo E, García de la Peña Lefebvre P, Eyerich K, Cosentino V, Alegre-Sancho JJ, Kowal-Bielecka O, Rey G, Matucci-Cerinic M, Allanore Y; EUSTAR group.

Ann Rheum Dis. 2017 Nov;76(11):1897-1905. doi: 10.1136/annrheumdis-2017-211448. Epub 2017 Aug 23.

PMID:
28835464
41.

Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis.

Avouac J, Guignabert C, Hoffmann-Vold AM, Ruiz B, Dorfmuller P, Pezet S, Amar O, Tu L, Van Wassenhove J, Sadoine J, Launay D, Elhai M, Cauvet A, Subramaniam A, Resnick R, Hachulla E, Molberg Ø, Kahan A, Humbert M, Allanore Y.

Arthritis Rheumatol. 2017 Nov;69(11):2209-2221. doi: 10.1002/art.40229. Epub 2017 Oct 17.

42.

Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.

Avouac J, Konstantinova I, Guignabert C, Pezet S, Sadoine J, Guilbert T, Cauvet A, Tu L, Luccarini JM, Junien JL, Broqua P, Allanore Y.

Ann Rheum Dis. 2017 Nov;76(11):1931-1940. doi: 10.1136/annrheumdis-2016-210821. Epub 2017 Aug 11.

PMID:
28801346
43.

Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis.

Carreira PE, Carmona L, Joven BE, Loza E, Andreu JL, Riemekasten G, Vettori S, Allanore Y, Balbir-Gurman A, Airò P, Walker UA, Damjanov N, Ananieva LP, Rednic S, Czirják L, Distler O, Farge D, Hesselstrand R, Corrado A, Caramaschi P, Tikly M, Matucci-Cerinic M; and EUSTAR co-authors.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):114-121. Epub 2017 Jun 20.

PMID:
28664832
44.

Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease.

Caforio ALP, Adler Y, Agostini C, Allanore Y, Anastasakis A, Arad M, Böhm M, Charron P, Elliott PM, Eriksson U, Felix SB, Garcia-Pavia P, Hachulla E, Heymans S, Imazio M, Klingel K, Marcolongo R, Matucci Cerinic M, Pantazis A, Plein S, Poli V, Rigopoulos A, Seferovic P, Shoenfeld Y, Zamorano JL, Linhart A.

Eur Heart J. 2017 Sep 14;38(35):2649-2662. doi: 10.1093/eurheartj/ehx321. No abstract available.

PMID:
28655210
45.

Cardiovascular magnetic resonance in systemic sclerosis: "Pearls and pitfalls".

Mavrogeni SI, Schwitter J, Gargani L, Pepe A, Monti L, Allanore Y, Matucci-Cerinic M.

Semin Arthritis Rheum. 2017 Aug;47(1):79-85. doi: 10.1016/j.semarthrit.2017.03.020. Epub 2017 Mar 31. Review.

PMID:
28522072
46.

Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, Mayes M, Medsger T Jr, Merkel PA, Pope JE, Seibold JR, Steen V, Stevens W, Denton CP.

J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231.

47.

Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group.

Jaeger VK, Distler O, Maurer B, Czirják L, Lóránd V, Valentini G, Vettori S, Del Galdo F, Abignano G, Denton C, Nihtyanova S, Allanore Y, Avouac J, Riemekasten G, Siegert E, Huscher D, Matucci-Cerinic M, Guiducci S, Frerix M, Tarner IH, Garay Toth B, Fankhauser B, Umbricht J, Zakharova A, Mihai C, Cozzi F, Yavuz S, Hunzelmann N, Rednic S, Vacca A, Schmeiser T, Riccieri V, García de la Peña Lefebvre P, Gabrielli A, Krummel-Lorenz B, Martinovic D, Ancuta C, Smith V, Müller-Ladner U, Walker UA.

Rheumatology (Oxford). 2018 Mar 1;57(3):441-450. doi: 10.1093/rheumatology/kex182.

PMID:
28499034
48.

Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis.

Juge PA, Borie R, Kannengiesser C, Gazal S, Revy P, Wemeau-Stervinou L, Debray MP, Ottaviani S, Marchand-Adam S, Nathan N, Thabut G, Richez C, Nunes H, Callebaut I, Justet A, Leulliot N, Bonnefond A, Salgado D, Richette P, Desvignes JP, Lioté H, Froguel P, Allanore Y, Sand O, Dromer C, Flipo RM, Clément A, Béroud C, Sibilia J, Coustet B, Cottin V, Boissier MC, Wallaert B, Schaeverbeke T, Dastot le Moal F, Frazier A, Ménard C, Soubrier M, Saidenberg N, Valeyre D, Amselem S; FREX consortium, Boileau C, Crestani B, Dieudé P.

Eur Respir J. 2017 May 11;49(5). pii: 1602314. doi: 10.1183/13993003.02314-2016. Print 2017 May.

49.

Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis.

Beyer C, Huscher D, Ramming A, Bergmann C, Avouac J, Guiducci S, Meier F, Vettori S, Siegert E, Jaeger VK, Maurer B, Riemekasten G, Walker U, Müller-Ladner U, Valentini G, Matucci-Cerinic M, Allanore Y, Distler O, Schett G, Distler JHW.

Ann Rheum Dis. 2018 Apr;77(4):626-628. doi: 10.1136/annrheumdis-2016-210834. Epub 2017 May 11. No abstract available.

PMID:
28495672
50.

Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definition.

Suliman YA, Bruni C, Johnson SR, Praino E, Alemam M, Borazan N, Cometi L, Meyers B, Khanna D, Allanore Y, Baron M, Krieg T, Herrick A, Afonso A, Distler O, Kafaja S, Denton CP, Matucci-Cerinic M, Furst DE.

J Scleroderma Relat Disord. 2017 May;2(2):115-120. doi: 10.5301/jsrd.5000236. Epub 2017 May 19.

Supplemental Content

Loading ...
Support Center